-Reuters
Analyst Says This Small Cap Biotech Firm Has ‘Very Valuable Therapeutic,’ Upgrades Stock
Raymond James has upgraded Dyne Therapeutics Inc (NASDAQ:DYN) from Outperform to Strong Buy and raised the price target to $27 from $16.…
Related Posts
Alimera Announces Multiple Presentations Highlighting ILUVIEN And YUTIQ Data At Retina Society Annual Congress
Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer,
Minim Launches Live Shopping Experience With HSN
Broadcast Shopping Segment Showcases Home Network Security Upgrades With Motorola WiFi 6 Mesh Portfolio
MANCHESTER, NH, Dec. 22, 2022 (GLOBE NEWSWIRE) -- ia NewMediaWire – Minim, Inc.,
Modine’s Strong Position In Data Center And EV Component Markets Compels Analyst To Boost Price Target
DA Davidson analyst Matt J.